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Abstract  24 
Background. Since there is clinical evidence for an association between periodontal 25 
disease and rheumatoid arthritis, it is important to develop suitable experimental 26 
models to explore pathogenic mechanisms and therapeutic opportunities. 27 
Methodology. The K/BxN serum model of inflammatory arthritis was applied using 28 
distinct protocols, and modulation of joint disruption afforded by dexamethasone and 29 
calcitonin, in comparison to the melanocortin (MC) receptor agonist DTrp8-γMSH 30 
(DTrp), established. Wild type and MC receptor type 3 (MC3) null mice of different 31 
ages were also used. 32 
Results. There was significant association between severity of joint disease, induced 33 
with distinct protocols and volumes of the arthritogenic K/BxN serum, and periodontal 34 
bone damage. Therapeutic treatment with dexamethasone (10μg/mouse), elcatonin 35 
(30ng/mouse) and DTrp (20μg/mouse) revealed unique and distinctive 36 
pharmacological properties, with only DTrp protecting both joint and periodontal 37 
tissue. Further analyses in non-arthritic animals revealed higher susceptibility to 38 
periodontal bone loss in Mc3r-/- compared to wild type mice, with significant 39 
exacerbation at 14 weeks of age. 40 
Significance. These data reveal novel protective properties of endogenous MC3 on 41 
periodontal status in health and disease and indicate that MC3 activation could lead 42 
to the development of a new genus of anti-arthritic bone-sparing therapeutics. 43 
 44 
 45 
Keywords: Dexamethasone, Inflammatory Arthritis, K/BxN arthritis model, 46 
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1. Introduction 49 
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with 50 
progressive disability, early death, increased risk of cardiovascular events and other 51 
extra-articular manifestations that have a major impact in the quality of life of 52 
sufferers [1,2]. The current clinical approach is to start early, after diagnosis, with 53 
aggressive therapy, followed by treatment adjustments according to changes in 54 
disease activity. However, despite the important progress in RA therapies during the 55 
last decade several needs are still unmet. The introduction of biologics in the early 56 
‘90s revolutionized the treatment of RA and other chronic diseases such as 57 
inflammatory bowel disease. However, although highly effective and generally faster 58 
acting than disease-modifying anti-rheumatic drugs (DMARDs) a significant 59 
proportion of patients are not responsive, and may also experience an increased risk 60 
of opportunistic infections and treatments are costly [3]. Thus there is justification for 61 
exploiting novel therapies. Additionally, it is also desirable to produce new 62 
therapeutics with efficacy not only on pain and inflammation in the joint, but also able 63 
to temper systemic complications of RA affecting the heart, lungs, muscles and bone 64 
[1]. 65 
Targeting the melanocortin (MC) system [4] to treat RA may represent an alternative 66 
opportunity to drug discovery [5]. Indeed, one of the melanocortin agonists ACTH 67 
(adrenocorticotropin hormone) was shown to be effective in human RA over 60 years 68 
ago [6], yet it is truly experiencing a renewed interest [7]. This is prompted by the fact 69 
that ACTH may afford biological actions beyond the endogenous production of 70 
cortisol [8,9], provoking activation of peripheral MC receptors, including the 71 
melanocortin receptor 3 (MC3). This peripheral mechanism of action of ACTH, hence 72 
independent from adrenal release of glucocorticoids, might also underlie efficacy in 73 
conditions such as proteinuric nephropathies [10] and multiple sclerosis [11]. 74 
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Surmounting evidence indicates an important counter-regulatory role for the 75 
melanocortin pathway during inflammation, including in the osteo-articular system, 76 
where melanocortin receptors are expressed by osteoblasts, osteoclasts, 77 
chondrocytes, fibroblasts and immune cells. Pharmacological targeting with MC 78 
peptides leads to a variety of protective actions including increased matrix deposition, 79 
reduced fibroblast activation, osteoblast and chondrocyte proliferation 80 
[12,13,14,15,16,17]. In vivo, the synthetic peptide DTrp8-γMSH (DTrp) reduces 81 
clinical signs of disease in models of inflammatory arthritis [18] and urate crystal 82 
peritonitis [19] by a mechanism involving MC3. In addition, the pan-MC agonist 83 
peptide AP214 also displays anti-arthritic properties [20].  Recent work by Gomez-84 
SanMiguel et al, reported that the MC agonist alpha-melanocyte stimulating hormone 85 
(αMSH) can reduce joint inflammation together with an improvement of extra-articular 86 
signs associated with systemic arthritis, by increasing body weight and reducing 87 
levels of muscle wasting markers [21].  88 
An important clinical manifestation associated with arthritis is periodontal disease. 89 
There is epidemiological evidence associating inflammation of the gum to incidence 90 
of RA [22] and, conversely, there is higher incidence of periodontitis in RA patients 91 
[23]. Intriguingly, recent reports demonstrated presence of alveolar bone loss, an 92 
important feature of periodontitis, in rodents during the time course of experimental 93 
models of arthritis, namely collagen-induced and adjuvant-induced arthritis 94 
[24,25,26]. Herein, we investigated the presence of alveolar bone loss in a different 95 
model of experimental arthritis; one induced by the arthritogenic K/BxN serum which 96 
is much faster in its kinetics, and it is characterized by leukocyte infiltration, 97 
synoviocyte proliferation, cartilage and bone erosion, thus resembling many features 98 
of human RA in its active flares [27,28], In addition, we established the involvement 99 
of the melanocortin system in the development of alveolar bone loss by using a 100 
combination of genetically engineered mice and pharmacological approaches. 101 
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2. Materials and Methods 102 
2.1. Animals. 103 
Male mice (7-8 weeks old) were maintained on standard chow pellet diet and had 104 
free access to water with a 12-hour light-dark cycle. C57BL/6J wild-type (WT) were 105 
purchased from Charles River (Kent, UK). Mc3r-/- mice were a generous gift of Dr 106 
Chen (Merck Laboratories). All animal studies were approved and performed under 107 
the guidelines of the Ethical Committee for the Use of Animals, Barts and The 108 
London School of Medicine and Home Office Regulations (Guidance on the 109 
Operation of Animals, Scientific Procedures Act, 1986). 110 
2.2. Production of K/BxN serum 111 
 K/BxN mice were produced by crossing the C57B1/6 mice (carrying the KRN 112 
homozygously) and the NOD/Lt mice (carrying the Ag7 allele homozygously) [27]. The 113 
offspring develop spontaneous arthritis, evident at 6 weeks, with 100% incidence. At 114 
9 weeks of age (when the titers of anti-glucose-6-phosphate isomerase (GPI) 115 
antibodies are maximal implying potent arthritogenic properties of the serum) mice 116 
were exsanguinated by cardiac puncture under anaesthesia (isofluorane). Blood was 117 
allowed to clot overnight at 4°C. Serum was recovered with a Pasteur pipette and 118 
centrifuged 10 min at 500xg at 4°C. The serum from different mice obtained on a 119 
given day was pooled, aliquoted and stored at -80°C until use. 120 
2.3. K/BxN serum transfer arthritis model. 121 
Arthritis was induced by the i.p. injection of serum from K/BxN arthritic mice. Three 122 
different protocols were studied: a) protocol 50+50, where mice received two 123 
injections of 50μl of serum on days 0 and 2; b) protocol 100+100, where mice 124 
received two injections of 100μl of serum on days 0 and 2; c) protocol 200, consisting 125 
of one single injection of 200μl of serum on day 0. The protocol 100+100 was then 126 
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selected for subsequent experiments. The development of the disease was 127 
monitored daily by assessing the paw volume using a plethysmometer (Ugo Basile, 128 
Comerio, Italy), body weight, clinical score (score per paw: 0= no signs of 129 
inflammation, 1=subtle inflammation, localized, 2=easily identified inflammation but 130 
localized, 3=evident inflammation, not localized; max score=12 per mouse) and 131 
disease incidence (mice showing overt signs of joint inflammation, i.e. a clinical score 132 
of 1 or above) [29]. Severe arthritis (number of paws per mouse that reached a 133 
maximum score of 3) was also recorded. 134 
2.4. Pharmacological treatments. 135 
Mice (n=5) were treated i.p. once daily, starting from day 2 (1h after the second 136 
K/BxN injection), with 10μg/mouse dexamethasone (SIGMA, Poole, UK), 137 
20μg/mouse DTrp8-γMSH (DTrp; American Peptide, Sunnyvale, CA, USA), 138 
30ng/mouse elcatonin (Bachem, Bubendorf, Switzerland) or vehicle (PBS). Doses 139 
were selected from previous studies in this or similar rodent models [18,30,31]. 140 
2.5. Measurement of alveolar bone loss. 141 
Alveolar bone loss was evaluated as previously described [32]. Mice were 142 
euthanized and maxillae were hemisected, exposed overnight in 3% hydrogen 143 
peroxide, mechanically defleshed, and stained with 0.3% methylene blue. The palatal 144 
faces of the molars were photographed using a stereomicroscope and a digital 145 
camera (Kodak EasyShare C743; Rochester, USA). Quantitative analyses included 146 
the measurement of the area between the cement enamel junction and the alveolar 147 
bone crest in the first molar, using Image J software (Maryland, USA). 148 
2.6. Myeloperoxydase activity assay. 149 
MPO activity was measured as an index of granulocyte infiltration. Briefly, maxillae 150 
tissue samples were homogenized in 0.5% hexadecyltrimethylammonium bromide 151 
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dissolved in phosphate buffer solution (pH = 6) using Precellys®24 homogeniser in 152 
Precellys lysing CK14 tubes (Bertin Technologies). The homogenized tissues were 153 
centrifuged at 13 000xg for 5 minutes (at 4°C) and the supernatants were placed on 154 
96 well plates. Buffer, supplemented with 1% hydrogen peroxide/O-dianisidine 155 
dihydrocholoride, was added to each well. Optical density readings were taken for 3 156 
minutes at 30 seconds intervals at 450 nm using a microplate reader NOVOstar™ 157 
(BMG Labtech, Aylesbury, UK). Activity was normalized to the sample protein 158 
concentration determined with a BCA kit® (Pierce, Cramlington, UK) and expressed 159 
as mU/mg protein. 160 
2.7. Histological analyses. 161 
Maxillae tissues were fixed in 10% buffered formalin (pH 7.4) for 24 h at room 162 
temperature. The specimens were demineralized in 14% ethylenediamine tetracetic 163 
acid (EDTA) for 2 weeks, dehydrated in graded ethanol and embedded in paraffin. 164 
Serial sections (5 μm) were stained for tartrate-resistant acid phosphatase (TRAP, 165 
Sigma–Aldrich, Saint Louis, MO, USA). Histological osteoclast counting was 166 
performed in the coronal two thirds of the distal alveolar bone adjacent to the first 167 
molar in five consecutive microscopic fields (40x)/section. Samples were analyzed 168 
using an Axioskop 40 microscope (Carl Zeiss, Gottingen, Germany), attached to a 169 
digital camera (PowerShot A620; Canon, Tokyo, Japan). For each animal (n=4), 170 
three maxillae sections were analyzed. All the slides were counted in a blinded 171 
manner by a single examiner. For neutrophil staining tissue specimens were blocked 172 
by incubation in 1.5% H2O2 in methanol solution for 30 min. Primary antibody against 173 
neutrophil elastase (Santa Cruz Biotechnology, Heidelberg, Germany) was used with 174 
Vectastain ABC kit anti-rabbit (Vector Laboratories, Burlingame, USA). The sections 175 
were counterstained using hematoxylin. Slides were developed using Peroxidase 176 
substrate kit DAB Kit (Vector Laboratories, Burlingame, USA). 177 
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2.8 Statistical analysis 178 
Data were analyzed by Student’s t-test, one or two-way ANOVA followed by 179 
Bonferroni or multiple comparison test, two-way ANOVA followed Newman-Keuls 180 
multiple comparison test or Pearson correlation test, as appropriate. In all cases data 181 
are presented as mean ± SEM of n independent observations and were considered 182 
statistically significant when p<0.05. 183 
184 
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3. Results 185 
3.1. Arthritis severity in the K/BxN serum transfer model correlates with alveolar bone 186 
loss. 187 
Recent reports have indicated that experimental models of collagen and antigen-188 
induced arthritis are associated with development of alveolar bone loss. We 189 
evaluated whether development of aggressive joint inflammation using the K/BxN 190 
serum transfer model of arthritis was also associated with this extra-articular 191 
manifestation. We therefore utilized three dosing strategies to manipulate the severity 192 
of arthritis: mice received two injections of either 50μl or 100μl of serum on days 0 193 
and 2 (protocol 50+50 or protocol 100+100 respectively) or a single injection of 200μl 194 
of serum on day 0; protocol 200. All three regimens induced overt signs of arthritis. 195 
As expected, the arthritic response produced with protocol 50+50 was milder, 196 
evidenced by the low clinical score (Figure 1A), inconsistent increase in paw volume 197 
(Figure 1B) and reduced severity (Figure 1C) compared with the other two protocols. 198 
Comparatively, although mice received the same total amount of arthritogenic serum 199 
using protocols 100+100 and 200, administration in two separate injections (day 0 200 
and 2) resulted in higher clinical scores, more gradual and consistent increase in paw 201 
volume and, importantly, 100% disease incidence (Figure 1D). We next analysed 202 
alveolar bone loss in the maxillae of these mice subjected to serum transfer-induced 203 
arthritis. Interestingly, bone loss in the maxillae was highly correlated with the 204 
severity of localized inflammation in the joints (Figure 2A), suggesting that extra-205 
articular manifestations of relevance for RA also occur in this model. An overall 206 
comparison between non-arthritic and arthritic mice indicated a significant (21%) 207 
increase in alveolar bone loss (Figure 2B). This could also be seen macroscopically 208 
by an increased corono-apical area between the cement enamel junction (CEJ) and 209 
the alveolar bone crest (ABC) on the palatal side of the first molar (Figure 2C).  210 
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3.2. Melanocortin treatment reduces arthritis and prevents alveolar bone loss. 211 
The melanocortin system is widely associated with joint disease and inflammation 212 
both mechanistically and therapeutically [5,8,18,19]. We studied if pharmacological 213 
intervention with melanocortin-based compounds could have an impact, not only in 214 
joint inflammation or other arthritis-related manifestations like cachexia, as recently 215 
described [21], but also in alveolar bone loss. We therefore assessed whether the 216 
peptide DTrp could prevent the development of alveolar bone loss we observed 217 
using this passive transfer model of arthritis. Dexamethasone (Dex), very potent as 218 
an anti-inflammatory drug but with detrimental bone effects, and elcatonin (ECT), a 219 
bone protective molecule but with mild anti-inflammatory effects, were used for 220 
comparison. As expected Dex afforded a potent anti-inflammatory effect, reducing 221 
clinical score (-40% at day 8; Figure 3A), paw volume (-59%; Figure 3B), and 222 
incidence of severe arthritis (-93%; Figure 3C). The effect of ECT was less 223 
pronounced with a significant statistical difference only in reducing paw volume. DTrp 224 
presented a moderate and significant attenuation in all parameters measured (clinical 225 
score -23%, paw volume -44%, severity -57%).  226 
Determination of myeloperoxidase (MPO) activity in maxillae tissues (analyzed at day 227 
8) showed a significant reduction in the groups treated with either Dex or DTrp, but 228 
not with ECT (Figure 3E). Although the degree of anti-inflammatory activity attained 229 
by treatment of animals with Dex and DTrp in the periodontal tissue appears to be 230 
similar, assessment of alveolar bone loss revealed interesting differences: the anti-231 
arthritic effect of DTrp is associated with bone protection, as evident from the positive 232 
correlation (R=0.87) between bone loss and clinical score (Figure 3F). In contrast, 233 
the anti-arthritic effect of Dex was inversely correlated with alveolar bone loss (R=-234 
0.87), in accordance with the well-known effects of Dex on bone metabolism. These 235 
findings suggest that melanocortin therapy, in addition to potent modulation of 236 
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inflammation and arthritis, could also have the advantage over corticoids therapy in 237 
preserving bone integrity. 238 
 239 
3.4. MC3 deficient mice display increased alveolar bone loss. 240 
Our next approach consisted of the study of the role of the melanocortin receptor 3 241 
(MC3) using genetically modified mice lacking this receptor, as it has been reported 242 
that MC3 is as pivotal target for the anti-inflammatory and anti-arthritic actions of 243 
melanocortin drugs, including ACTH [8,9]. Arthritis was induced using the 100+100 244 
protocol, as in previous experiments, although in this case 12-week old mice were 245 
used (due to stock availability). As shown in Figure 4, arthritis developed similarly to 246 
previous experiments with younger mice. The clinical score and disease severity was 247 
identical in WT and Mc3r-/- mice although some differences were found in the paw 248 
volume (Figure 4). As expected, when alveolar bone loss was assessed in maxillae 249 
(day 8), WT arthritic mice presented an increase in bone loss corroborating our 250 
previous findings. However, the basal values of alveolar bone loss obtained in Mc3r-251 
/- mice were elevated compared with WT mice, and no further alveolar bone loss was 252 
obtained following arthritis induction (Figure 4D). The fact that the mice used in this 253 
experiment were older made us hypothesise that there might be an association 254 
between MC3 deficiency and physiological bone metabolism. 255 
 256 
3.5. Aging-associated alveolar bone loss is accelerated in MC3 deficient mice. 257 
The evidence obtained in our previous experiments suggests that activation of MC3 258 
(the main receptor that mediates DTrp actions [19]) might protect from alveolar bone 259 
loss. Since there is evidence in the literature furthering an association between the 260 
melanocortin system and bone metabolism [12], as well as linking normal bone loss 261 
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associated with aging [33,34], next we sought to investigate if MC3 played any role in 262 
these phenomena. 263 
Maxillae from WT and Mc3r-/- mice harvested at different ages (1.5, 3.5 and 4.5 264 
months old) were analyzed for alveolar bone loss. Interestingly, periodontal bone loss 265 
was accelerated in Mc3r-/- mice, showing a 39% increase at 3.5 months of age 266 
compared to younger mice (1.5 months), while only 15% increase was observed in 267 
same age WT mice (Figure 5).  268 
There is some indication for a functional association between MC3 and 269 
osteoclastogenesis, as the number of osteoclasts is increased in Mc3r-/- arthritic 270 
mice, compared to WT [18]. We then studied if osteoclasts numbers were also 271 
different in the maxillae of the two genotypes by quantifying the Trap+ cells in the 272 
cervical area of the first molar of the left lower maxillae (n=4 mice). Although basal 273 
levels (1.5 months/old) were different, we quantified a 40% increase in Trap+ cells in 274 
older mice in Mc3r-/- but not in WT mice, where values remained stable (Figure 6A). 275 
We also observed a significant increase in the number of neutrophils in the junctional 276 
epithelium of Mc3r-/- mice compared to WT (Figure 6B). However, no differences 277 
were found in the rest of epithelial and connective tissue suggesting that neutrophils 278 
might not be playing a crucial role in the alveolar bone loss as measured in our 279 
experimental conditions. 280 
281 
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4. Discussion 282 
There is clinical evidence that periodontal disease is associated with RA, although it 283 
is unclear whether the link is causal or casual. Bone resorption in the maxillae 284 
(associated with a high degree of immune cell infiltration) is reminiscent of the RA 285 
joint where large numbers of blood-borne cells can be found in the exudate during 286 
the active phases of the disease. To gain information on pathogenesis to 287 
subsequently inform on therapeutic opportunities, it is important to develop animal 288 
models where disease development could be monitored at the two sites in parallel.  289 
 290 
The recent appreciation that mice subjected to the gold standard model of RA, 291 
collagen induced arthritis, develop alveolar bone loss that parallel ankle joint damage 292 
[25] represents an important conceptual and experimental advance. Park et al 293 
reported severe periodontal bone damage 16 weeks after induction of arthritis using 294 
type-II collagen: this was associated with increased osteoclastic activity and impaired 295 
repair ability due to reduced bone formation by osteoblasts [25]. Here we used the 296 
K/BxN serum model of inflammatory arthritis, an aggressive model that mimics the 297 
active phases of RA and it is much faster in its onset. Injection of the serum rich in 298 
anti-glucose-6-phosphate isomerase immunoglobulins fixes complement onto 299 
cartilage with initiation of an inflammatory reaction, highly reliant on cytokines and 300 
eicosanoids [27,29]. Herein we first determined whether this rapid model (~7-8 days 301 
against >30 days for the collagen-induced arthritis) also led to periodontal disease. 302 
Thus, administration of the arthritogenic serum along three different protocols 303 
induced evident joint inflammation, with more consistent and reproducible data with 304 
the 100+100 µl protocol and truly mild when using the 50+50 µl protocol. A good 305 
association was observed between serum dosage and protocol of administration, 306 
which resulted in distinct severity of arthritis, and the corresponding degree of 307 
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alveolar bone loss measured in maxillae.  Collectively these data, coupled to the two 308 
recent studies [24,25] indicate that experimental polyarthritis in rodents is indeed 309 
associated with periodontal disease features. 310 
 311 
The melanocortin receptor agonist ACTH is an anti-arthritic drug indicated for the 312 
treatment of acute inflammatory episodes of gout [35] as well as RA, as shown by the 313 
seminal work of Hench and colleagues of the Mayo Clinic taught us [36,37]. The 314 
equally old observations of Gutman [6] have been repeated in more rigorous clinical 315 
studies confirming ACTH efficacy in human gouty arthritis [38,39,40]. All these 316 
studies indicate that ACTH is effective and safe for the treatment of acute gout and 317 
presents as a good alternative in patients with comorbidities in which steroids and 318 
colchicine are not recommended. Why is ACTH so effective in arthritides? Ritter and 319 
colleagues indicated the possible existence of mechanisms aside adrenal stimulation 320 
and glucocorticoid release [40], inciting us to identify peripheral modulation of MC3 as 321 
a very important contributor of the anti-inflammatory actions of the peptide [8]. 322 
However, ACTH is a pan-MC receptor agonist.  Herein we used peptide DTrp8-γMSH 323 
(abbreviated DTrp), which although not totally selective in in vitro expression cell 324 
systems, retains functional selectivity in the mouse as demonstrated by its lack of 325 
efficacy in Mc3r-/- animals. Importantly, DTrp displays anti-arthritic effects in the 326 
K/BxN animal model of arthritis [18,19,41].  327 
 328 
The pharmacological experiments suggested that MC-based therapy may yield a 329 
unique opportunity.  Whilst the glucocorticoid dexamethasone afforded the expected 330 
therapeutic effect on the arthritic joint [18], measured in terms of score, swelling, 331 
disease severity and MPO activity, it did not affect – and rather worsened – alveolar 332 
bone loss. This effect can be chiefly due to the osteoclast activating property of 333 
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glucocorticoids [42]. Calcitonin, on the other hand, was selected because 334 
representing an opposite therapeutic, with very little modulation of inflammatory 335 
arthritis [43] yet its daily delivery to mice from day 2 significantly protected from 336 
alveolar bone loss associated with this model of experimental arthritis. This was 337 
predicted in view of the potent action of calcitonin in stopping bone resorption [44], 338 
being able for instance to override the activating effect of glucocorticoids [43]. 339 
 340 
DTrp revealed unique properties since was able to inhibit arthritis, albeit to an 341 
intermediate level between dexamethasone and calcitonin, and also attenuate bone 342 
loss associated with periodontal disease. In more detail, the DTrp group showed a 343 
positive high correlation between clinical score and bone loss (i.e. reduced bone loss 344 
associated with the anti-arthritic effect, R=0.87), and this was the exact opposite of 345 
that calculated for Dex-treated mice (R=-0.87). This finding is of relevance as 346 
prolonged steroid therapy is associated with bone density loss, osteoporosis and 347 
fractures. These results indicate that MC receptor agonists, possibly better if 348 
selective for MC3, represent a novel class of anti-arthritic therapeutics able to target 349 
joint disease without aggravating unwanted effects on distant organs and tissues.  350 
This notion is further substantiated by a recent study where the beneficial effect of 351 
melanocortin treatment on joint inflammation and against systemic muscle wasting 352 
(cachexia) was demonstrated [21]. 353 
 354 
The bone-protective effect of DTrp is likely due a direct osteoclast effect that it is 355 
additive to modulation of local inflammation, as shown by the MPO activity 356 
measurements in maxillae samples. In agreement with these pharmacological data, 357 
we have reported a higher degree of osteoclastogenesis in Mc3r-/- mice, measured 358 
both in vivo in arthritic joints and in vitro, using bone marrow derived osteoclasts [18]. 359 
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Furthermore, in wild type osteoclasts, application of DTrp reduced cell activation and 360 
resorptive activity. In these experiments, Mc3r-/- mice did not presented more 361 
pronounced arthritis, at variance from what we reported previously [18], likely due to 362 
differences in protocol and animal age. On the same token though, this new result 363 
allows to separate periodontal bone loss and joint arthritis, indicating that the former 364 
occurs independently from modulation of the latter. Collectively, these data prompt us 365 
to identify MC3 as a modulatory receptor on osteoclast differentiation and activation. 366 
 367 
The use of genetically engineered mice can shed new insights into the biological 368 
functions of genes of interest. The involvement of MC3 in bone metabolism emerges 369 
from pharmacological evidence or from the use of Mc3r-/- in settings of experimental 370 
pathology.  But if MC3 plays important non-redundant role in bone physiology, then 371 
its absence might produce a phenotype in ‘healthy’ mice. Indeed, these mice present 372 
decreased linear growth and femur length as well as reduced bone mineral density 373 
[45,46]. To this end we monitored the degree of bone erosion in the maxillae of mice 374 
at different ages, comparing wild type and Mc3r-/- animals.  These experiments 375 
confirmed a higher susceptibility to alveolar bone loss in the transgenic lacking the 376 
MC3 receptor, with presence of significant bone loss as early as 14 weeks of age, 377 
whilst wild type mice displayed similar degrees of damage at 18 weeks. Thus, 378 
endogenous MC3, possibly activated by circulating ACTH or αMSH, exerts a tonic 379 
inhibitory role on bone metabolism in the maxillae hence in its absence there is a 380 
higher susceptibility to bone loss hence disease. Though congruent with the data 381 
presented above, this hypothesis requires corroboration by future studies. With 382 
ageing Mc3r-/- mice become obese, an effect evident at 12 weeks of age [47]. Since 383 
it is reported that obese mice have a different microbiota compared to lean animals 384 
[48], one could not exclude that a different microbiota predisposes to higher 385 
susceptibility to periodontal disease. Again, focused and systematic analyses on the 386 
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periodontal compartment of MC3 deficient mice can shed light onto this novel biology 387 
of the MC system we have unveiled here. 388 
 389 
In summary, we describe a novel experimental association between periodontal 390 
disease and inflammatory arthritis with two distinct outcomes: first, the modulatory 391 
function of MC3 on periodontal status in health and disease; second, the distinct 392 
pharmacology of DTrp as compared to other anti-arthritic or bone-protective 393 
compounds, suggesting the potential development of a new genus of anti-arthritic 394 
therapeutics, centred on MC3 activation and able to spare or correct alveolar bone 395 
damage. 396 
397 
AJP14-0115v2  Montero—Melendez et al 
 18 
5. References 398 
1. McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med 399 
2011, 365: 2205-2219. 400 
2. Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G: 401 
Rheumatoid arthritis: from autoimmunity to synovitis and joint 402 
destruction. J Autoimmun 2012, 39: 222-228. 403 
3. Taylor PC: Developing anti-TNF and biologic agents. Rheumatology (Oxford) 404 
2011, 50: 1351-1353. 405 
4. Gantz I, Fong TM: The melanocortin system. Am J Physiol Endocrinol Metab 406 
2003, 284: E468-474. 407 
5. Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S: The melanocortin 408 
system in control of inflammation. ScientificWorldJournal 2010, 10: 1840-409 
1853. 410 
6. Gutman AB, Yu TF: Effects of adrenocorticotropic hormone (ACTH) in gout. Am 411 
J Med 1950, 9: 24-30. 412 
7. Cronstein BN, Terkeltaub R: The inflammatory process of gout and its 413 
treatment. Arthritis Res Ther 2006, 8 Suppl 1: S3. 414 
8. Getting SJ, Christian HC, Flower RJ, Perretti M: Activation of melanocortin type 415 
3 receptor as a molecular mechanism for adrenocorticotropic hormone 416 
efficacy in gouty arthritis. Arthritis Rheum 2002, 46: 2765-2775. 417 
9. Getting SJ, Gibbs L, Clark AJ, Flower RJ, Perretti M: POMC gene-derived 418 
peptides activate melanocortin type 3 receptor on murine macrophages, 419 
suppress cytokine release, and inhibit neutrophil migration in acute 420 
experimental inflammation. J Immunol 1999, 162: 7446-7453. 421 
10. Gong R: The renaissance of corticotropin therapy in proteinuric 422 
nephropathies. Nat Rev Nephrol 2012, 8: 122-128. 423 
11. Berkovich R: Treatment of acute relapses in multiple sclerosis. 424 
Neurotherapeutics 2013, 10: 97-105. 425 
12. Dumont LM, Wu CS, Tatnell MA, Cornish J, Mountjoy KG: Evidence for direct 426 
actions of melanocortin peptides on bone metabolism. Peptides 2005, 26: 427 
1929-1935. 428 
13. Cornish J, Callon KE, Mountjoy KG, Bava U, Lin JM, Myers DE, Naot D, Reid IR: 429 
alpha -melanocyte-stimulating hormone is a novel regulator of bone. Am J 430 
Physiol Endocrinol Metab 2003, 284: E1181-1190. 431 
14. Grassel S, Opolka A, Anders S, Straub RH, Grifka J, Luger TA, Bohm M: The 432 
melanocortin system in articular chondrocytes: melanocortin receptors, 433 
pro-opiomelanocortin, precursor proteases, and a regulatory effect of 434 
alpha-melanocyte-stimulating hormone on proinflammatory cytokines 435 
and extracellular matrix components. Arthritis Rheum 2009, 60: 3017-436 
3027. 437 
15. Evans JF, Niu QT, Canas JA, Shen CL, Aloia JF, Yeh JK: ACTH enhances 438 
chondrogenesis in multipotential progenitor cells and matrix production 439 
in chondrocytes. Bone 2004, 35: 96-107. 440 
16. Bohm M, Raghunath M, Sunderkotter C, Schiller M, Stander S, Brzoska T, 441 
Cauvet T, Schioth HB, Schwarz T, Luger TA: Collagen metabolism is a 442 
novel target of the neuropeptide alpha-melanocyte-stimulating hormone. 443 
J Biol Chem 2004, 279: 6959-6966. 444 
AJP14-0115v2  Montero—Melendez et al 
 19 
17. Bohm M, Luger TA: Melanocortins in fibroblast biology--current update and 445 
future perspective for dermatology. Exp Dermatol 2004, 13 Suppl 4: 16-446 
21. 447 
18. Patel HB, Bombardieri M, Sampaio AL, D'Acquisto F, Gray M, Grieco P, Getting 448 
SJ, Pitzalis C, Perretti M: Anti-inflammatory and antiosteoclastogenesis 449 
properties of endogenous melanocortin receptor type 3 in experimental 450 
arthritis. FASEB J 2010, 24: 4835-4843. 451 
19. Getting SJ, Lam CW, Chen AS, Grieco P, Perretti M: Melanocortin 3 receptors 452 
control crystal-induced inflammation. FASEB J 2006, 20: 2234-2241. 453 
20. Montero-Melendez T, Patel HB, Seed M, Nielsen S, Jonassen TE, Perretti M: 454 
The melanocortin agonist AP214 exerts anti-inflammatory and 455 
proresolving properties. Am J Pathol 2011, 179: 259-269. 456 
21. Gomez-Sanmiguel AB, Martin AI, Nieto-Bona MP, Fernadez-Galaz C, Lopez-457 
Menduina M, Villanua MA, Lopez-Calderon A: Systemic alpha melanocyte 458 
stimulating hormone administration decreases arthritis-induced anorexia 459 
and muscle wasting. Am J Physiol Regul Integr Comp Physiol 2013. 460 
22. Scher JU, Abramson SB: Periodontal disease, Porphyromonas gingivalis, and 461 
rheumatoid arthritis: what triggers autoimmunity and clinical disease? 462 
Arthritis Res Ther 2013, 15: 122. 463 
23. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, 464 
Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA, Abramson 465 
SB: Periodontal disease and the oral microbiota in new-onset rheumatoid 466 
arthritis. Arthritis Rheum 2012, 64: 3083-3094. 467 
24. Queiroz-Junior CM, Madeira MF, Coelho FM, Costa VV, Bessoni RL, Sousa LF, 468 
Garlet GP, Souza Dda G, Teixeira MM, Silva TA: Experimental arthritis 469 
triggers periodontal disease in mice: involvement of TNF-alpha and the 470 
oral Microbiota. J Immunol 2011, 187: 3821-3830. 471 
25. Park JC, Su C, Jung IH, Choi SH, Cho KS, Kim CK, Park YB, Lee SK, Kim CS: 472 
Mechanism of alveolar bone loss in a collagen-induced arthritis model in 473 
mice. J Clin Periodontol 2011, 38: 122-130. 474 
26. Queiroz-Junior CM, Madeira MF, Coelho FM, de Oliveira CR, Candido LC, 475 
Garlet GP, Teixeira MM, de Souza Dda G, Silva TA: Experimental arthritis 476 
exacerbates Aggregatibacter actinomycetemcomitans-induced 477 
periodontitis in mice. J Clin Periodontol 2012, 39: 608-616. 478 
27. Monach PA, Mathis D, Benoist C: The K/BxN arthritis model. Curr Protoc 479 
Immunol 2008, Chapter 15: Unit 15 22. 480 
28. Ditzel HJ: The K/BxN mouse: a model of human inflammatory arthritis. 481 
Trends Mol Med 2004, 10: 40-45. 482 
29. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB: Mast cells: a 483 
cellular link between autoantibodies and inflammatory arthritis. Science 484 
2002, 297: 1689-1692. 485 
30. Patel HB, Kornerup KN, Sampaio AL, D'Acquisto F, Seed MP, Girol AP, Gray M, 486 
Pitzalis C, Oliani SM, Perretti M: The impact of endogenous annexin A1 on 487 
glucocorticoid control of inflammatory arthritis. Ann Rheum Dis 2012, 71: 488 
1872-1880. 489 
31. Al-Kashi A, Montero-Melendez T, Moradi-Bidhendi N, Gilligan JP, Mehta N, 490 
Perretti M: The calcitonin and glucocorticoids combination: mechanistic 491 
insights into their class-effect synergy in experimental arthritis. PLoS One 492 
2013, 8: e54299. 493 
AJP14-0115v2  Montero—Melendez et al 
 20 
32. Madeira MF, Queiroz-Junior CM, Costa GM, Santos PC, Silveira EM, Garlet GP, 494 
Cisalpino PS, Teixeira MM, Silva TA, Souza Dda G: MIF induces osteoclast 495 
differentiation and contributes to progression of periodontal disease in 496 
mice. Microbes Infect 2012, 14: 198-206. 497 
33. Liang S, Hosur KB, Domon H, Hajishengallis G: Periodontal inflammation and 498 
bone loss in aged mice. J Periodontal Res 2010, 45: 574-578. 499 
34. Rivaldo EG, Padilha DP, Hugo FN: Alveolar bone loss and aging: a model for 500 
the study in mice. J Periodontol 2005, 76: 1966-1971. 501 
35. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, 502 
Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote 503 
F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, 504 
Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, 505 
Schumacher HR, Robbins M, Wenger N, Terkeltaub R: 2012 American 506 
College of Rheumatology guidelines for management of gout. Part 2: 507 
therapy and antiinflammatory prophylaxis of acute gouty arthritis. 508 
Arthritis Care Res (Hoboken) 2012, 64: 1447-1461. 509 
36. Hench PS: Introduction: cortisone and ACTH in clinical medicine. Proc Staff 510 
Meet Mayo Clin 1950, 25: 474-476. 511 
37. Slocumb CH, Polley HF, Hench PS, Kendall EC: Effects of cortisone and ACTH 512 
on patients with rheumatoid arthritis. Proc Staff Meet Mayo Clin 1950, 25: 513 
476-478. 514 
38. Axelrod D, Preston S: Comparison of parenteral adrenocorticotropic hormone 515 
with oral indomethacin in the treatment of acute gout. Arthritis Rheum 516 
1988, 31: 803-805. 517 
39. Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP: ACTH as first 518 
line treatment for acute gout in 181 hospitalized patients. Joint Bone 519 
Spine 2013, 80: 291-294. 520 
40. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H: ACTH revisited: effective 521 
treatment for acute crystal induced synovitis in patients with multiple 522 
medical problems. J Rheumatol 1994, 21: 696-699. 523 
41. Leoni G, Patel HB, Sampaio AL, Gavins FN, Murray JF, Grieco P, Getting SJ, 524 
Perretti M: Inflamed phenotype of the mesenteric microcirculation of 525 
melanocortin type 3 receptor-null mice after ischemia-reperfusion. 526 
FASEB J 2008, 22: 4228-4238. 527 
42. Reid IR: Steroid-induced osteoporosis. Osteoporos Int 1997, 7 Suppl 3: S213-528 
216. 529 
43. Mancini L, Paul-Clark MJ, Rosignoli G, Hannon R, Martin JE, Macintyre I, 530 
Perretti M: Calcitonin and prednisolone display antagonistic actions on 531 
bone and have synergistic effects in experimental arthritis. Am J Pathol 532 
2007, 170: 1018-1027. 533 
44. Karsdal MA, Henriksen K, Arnold M, Christiansen C: Calcitonin: a drug of the 534 
past or for the future? Physiologic inhibition of bone resorption while 535 
sustaining osteoclast numbers improves bone quality. BioDrugs 2008, 22: 536 
137-144. 537 
45. Renquist BJ, Murphy JG, Larson EA, Olsen D, Klein RF, Ellacott KL, Cone RD: 538 
Melanocortin-3 receptor regulates the normal fasting response. Proc Natl 539 
Acad Sci U S A 2012, 109: E1489-1498. 540 
46. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, 541 
Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, 542 
AJP14-0115v2  Montero—Melendez et al 
 21 
Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van 543 
der Ploeg LH: Inactivation of the mouse melanocortin-3 receptor results 544 
in increased fat mass and reduced lean body mass. Nat Genet 2000, 26: 545 
97-102. 546 
47. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, 547 
Baetscher M, Cone RD: A unique metabolic syndrome causes obesity in 548 
the melanocortin-3 receptor-deficient mouse. Endocrinology 2000, 141: 549 
3518-3521. 550 
48. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An 551 
obesity-associated gut microbiome with increased capacity for energy 552 
harvest. Nature 2006, 444: 1027-1031. 553 
 554 
555 
AJP14-0115v2  Montero—Melendez et al 
 22 
List of abbreviations 556 
ACTH (adrenocorticotropic hormone), Dex (dexamethasone), DMARDs (disease-557 
modifying anti-rheumatic drugs), DTrp8-γMSH (DTrp), ECT (elcatonin), MC 558 
(melanocortin), MC3 (melanocortin receptor 3), myeloperoxydase (MPO), rheumatoid 559 
arthritis (RA), Trap (tartrate-resistant acid phosphatase), wild type (WT) 560 
 561 
Competing interests 562 
Authors declare no competing interests. 563 
 564 
Authors contributions 565 
TMM designed study, performed experiments, analyzed and interpreted data and 566 
wrote manuscript; MFMM performed experiments, analyzed and interpreted data and 567 
revised manuscript; LVN performed experiments and revised manuscript; AA 568 
performed experiments and revised manuscript; MAC interpreted data and revised 569 
manuscript; TAS interpreted data and revised manuscript; MP designed study, wrote 570 
manuscript and provided funding. 571 
 572 
573 
AJP14-0115v2  Montero—Melendez et al 
 23 
Figure Legends 574 
Figure 1. Comparison of three protocols for the K/BxN serum transfer arthritis model. 575 
Arthritis was induced by the i.p. injection of serum from K/BxN arthritic mice using 576 
three different protocols: 50+50 (two injections of 50μl on days 0 and 2); 100+100 577 
(two injections of 100μl on days 0 and 2); 200 (one single injection on day 0). Clinical 578 
score (A), paw volume (B) and disease incidence (C) were recorded for 7 days. 579 
Panel (D) shows the number of paws per mouse that reached the maximum score 580 
(3). Representative images of ankle, wrist and digits swelling are shown in panel (E). 581 
Data are the mean±SEM of 4-6 mice per group. *p<0.05 two-way ANOVA followed 582 
by Bonferroni multiple comparison test. 583 
 584 
Figure 2. Correlation of arthritis with alveolar bone loss in the K/BxN serum transfer 585 
model. Alveolar bone loss was evaluated at day 7 in the palatal aspect of the first 586 
upper molar of the right hemi-maxillae. (A) Correlation between alveolar bone loss 587 
and clinical score on mice studied in the protocol comparison experiment (see Figure 588 
1) analyzed by Pearson correlation test (n=14). (B) Overall increase in alveolar bone 589 
loss in arthritic mice (pooled data from all mice, mean±SEM, n=14) compared to 590 
control mice, analyzed by t-test (*p<0.05). (C) Representative photographs of the 591 
maxillae showing evidence of alveolar bone loss (white arrows). 592 
 593 
Figure 3. Effect of dexametasone, DTrp and elcatonin in arthritis and alveolar bone 594 
loss. Arthritis was induced using the 100+100 protocol (100μl of serum on days 0 and 595 
2) and monitored by daily recording the clinical score (A), paw volume (B), severity 596 
(number of paws reaching the maximum score) (C) and disease incidence (D). 597 
Myeloperoxidase activity was measured in the left hemi-maxillae at day 8 (E). 598 
Alveolar bone loss was analyzed in the right hemi-maxillae at day 8 and correlated 599 
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with clinical score recorded that day (F). Drugs were administered i.p. once daily: 600 
dexamethasone (Dex) 10μg/mouse; DTrp8-γMSH (DTrp) 20μg/mouse; elcatonin 601 
(ECT) 30ng/mouse; Vehicle PBS (Veh). Non-arthritic mice were included as controls 602 
(Ctrl). Data are the mean±SEM of 5-6 mice per group. Data were analyzed by two-603 
way ANOVA followed by Bonferroni multiple comparison test (A-C), one-way ANOVA 604 
followed by Bonferroni multiple comparison test (E) and Pearson correlation test (F). 605 
In all cases *p<0.05. 606 
 607 
Figure 4. Arthritis and alveolar bone loss in MC3 deficient mice. Arthritis was induced 608 
in C57BL/6J wild type mice (WT) and melanocortin receptor 3 deficient mice (Mc3r-/-) 609 
using the 100+100 protocol (100μl of serum on days 0 and 2). Disease was 610 
monitored by daily recording of the clinical score (A), paw volume (B), and disease 611 
severity (number of paws reaching the maximum score) (C). Alveolar bone loss was 612 
analyzed in the right hemi-maxillae on the last day of the experiment (day 8). Data 613 
are the mean±SEM of 5 mice per group. Statistical analyses were carried out by two-614 
way ANOVA followed by Bonferroni multiple comparison test (A-C) and one-way 615 
ANOVA followed by Newman-Keuls multiple comparison test vs. WT-Ctrl (D). In all 616 
cases *p<0.05. 617 
 618 
Figure 5. Impact of aging on alveolar bone loss in MC3 deficient mice. (A) Alveolar 619 
bone loss was evaluated in the right hemi-maxillae in mice from different ages (1.5, 620 
3.5 and 4.5 months old) in both C57BL/6J wild type mice (WT) and melanocortin 621 
receptor 3 deficient mice (Mc3r-/-). Data are the mean±SEM of 6-17 mice. Data were 622 
analyzed by two-way ANOVA followed by Bonferroni multiple comparison test, 623 
*p<0.05 vs. 1.5months, †p<0.05 WT vs. Mc3r-/-. 624 
 625 
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Figure 6. Analysis of osteoclasts and neutrophils in gingival tissues. The left hemi-626 
maxillae were used for histological evaluation of osteoclast activity by Trap staining 627 
and neutrophil infiltration. (A) The number of osteoclasts on the cervical area of the 628 
first molar was counted. Representative images of Trap+ cells are shown. (B) 629 
Sections were stained for neutrophil elastase as a marker of neutrophils. 630 
Representative images of 1.5 months old mice are shown. Data are the mean±SEM 631 
of 2-4 mice. Data were analyzed by one-way ANOVA followed by Bonferroni multiple 632 
comparison test, *p<0.05. 633 
634 
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Figure 2 638 
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Figure 3 641 
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Figure 4 644 
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